Rafael Holdings, Inc. 8K

Rafael Holdings, Inc. used a Form 8-K to furnish an investor presentation highlighting clinical and regulatory progress, market positioning, and funding status for its lead Niemann-Pick Disease Type C1 therapy Trappsol Cyclo, including planned NDA submission and topline Phase 3 data in the second half of 2026.

Rafael Holdings, Inc. furnished an investor presentation as an exhibit to its Form 8-K, providing an update on its lead clinical program Trappsol Cyclo for Niemann-Pick Disease Type C1, including completion of last patient last visit for its pivotal Phase 3 TransportNPC trial in June 2026, a prior positive interim Data Monitoring Committee recommendation to continue to final 96‑week analysis, completion of a pre-NDA meeting with regulators, plans to submit a New Drug Application and report topline data in the second half of 2026, supportive Phase 1/2 and extension study data, the evolving competitive landscape, and its financial position with approximately $30.5 million in cash as of April 30, 2026, which it believes is sufficient to fund operations through multiple potential value-creation milestones.

Filing Facts

CIK

1713863

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-076411

Alert Tier

6